FDA Blesses 2nd CAR-T Cell Therapy, NVO One Step Away From Approval, AKTX Slumps

Today's Daily Dose brings you news about Akari and Ignyta's public offering; Conatus' drug candidate securing orphan designation from the European Medicines Agency; FDA approval of Gilead's CAR-T therapy for refractory large B-cell lymphoma; FDA panel review of Lipocine's oral testosterone product candidate and FDA panel nod for Novo Nordisk's once-weekly Semaglutide.

from RTT - Biotech http://ift.tt/2kXKjgB
via IFTTT